dapagliflozin News
Most Popular dapagliflozin Story
FDA rejects dapagliflozin for diabetes, raising concerns for a class
The FDA has surprised no one with its decision to bat down dapagliflozin, an innovative but potentially risky new approach to treating diabetes. AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) Read more...
Latest Headlines
- January 26, 2012
- January 19, 2012
- June 23, 2011
- September 24, 2010
- September 20, 2010
- October 21, 2009
- October 2, 2009
- December 8, 2008
- September 11, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
